155 related articles for article (PubMed ID: 35171658)
1. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
McGregor BA; Xie W; Adib E; Stadler WM; Zakharia Y; Alva A; Michaelson MD; Gupta S; Lam ET; Farah S; Nassar AH; Wei XX; Kilbridge KL; Harshman L; Signoretti S; Sholl L; Kwiatkowski DJ; McKay RR; Choueiri TK
JCO Precis Oncol; 2022 Feb; 6():e2100448. PubMed ID: 35171658
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract][Full Text] [Related]
3. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Choueiri TK; Porta C; Suárez C; Hainsworth J; Voog E; Duran I; Reeves J; Czaykowski P; Castellano D; Chen J; Sedarati F; Powles T
Oncologist; 2022 Dec; 27(12):1048-1057. PubMed ID: 36146944
[TBL] [Abstract][Full Text] [Related]
5. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Rajdev L; Lee JW; Libutti SK; Benson AB; Fisher GA; Kunz PL; Hendifar AE; Catalano P; O'Dwyer PJ
Invest New Drugs; 2022 Dec; 40(6):1306-1314. PubMed ID: 36264382
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
11. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
García-Sáenz JÁ; Martínez-Jáñez N; Cubedo R; Jerez Y; Lahuerta A; González-Santiago S; Ferrer N; Ramos M; Alonso-Romero JL; Antón A; Carrasco E; Chen J; Neuwirth R; Galinsky K; Vincent S; Leonard EJ; Slamon D
Clin Cancer Res; 2022 Mar; 28(6):1107-1116. PubMed ID: 34980598
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
13. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Kessler ER; Callihan E; Hu J; Eule C; Srivastava G; Kemme DJ; Iruku P; Rana V; Moore J; Schuster SR; Amirault M; Flaig TW; Lam ET
Cancer Res Commun; 2023 Jun; 3(6):1004-1012. PubMed ID: 37377613
[TBL] [Abstract][Full Text] [Related]
15. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
[TBL] [Abstract][Full Text] [Related]
16. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Han SN; Oza A; Colombo N; Oaknin A; Raspagliesi F; Wenham RM; Braicu EI; Jewell A; Makker V; Krell J; Alía EMG; Baurain JF; Su Z; Neuwirth R; Vincent S; Sedarati F; Faller DV; Scambia G
Gynecol Oncol; 2023 Nov; 178():110-118. PubMed ID: 37839313
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]